CSPC Group (01093): Phase Ib/II clinical trial of SYS 6090 injection to treat hepatocellular carcinoma officially launched at the first center in China

Zhitong Finance App News, Shiyao Group (01093) announced that the SYS 6090 injection (phase Ib/II clinical trial of this product for the treatment of hepatocellular carcinoma (research plan number: SYS 6090-007) developed by the Group has officially launched at the first center in China.

This product is registered as a therapeutic biological product class 1. It is a fusion protein that recombinants whole human anti-programmed cell death receptor 1 (PD-1) and combines interleukin-15 (IL-15). It can target PD-1 positive tumors on the left arm to infiltrate immune cells, block immunosuppressive function caused by the interaction between PD-1 and programmed death ligand 1 (PD-L1); at the same time, it can bind to IL-15 receptors on its right arm to further promote the activation and proliferation of related immune cells. Preclinical research results show that the product can significantly inhibit tumor growth, is safe and well tolerated, and shows higher pharmacodynamic activity compared to other PD-1 monoclonal antibodies and IL-15 drugs.

Based on the results of this study, the Group will continue to advance phase III clinical research on the combined treatment of this product in hepatocellular carcinoma participants to further verify the efficacy and safety of this product. Currently, the recruitment and screening of subjects for the SYS 6090-007 study is being actively promoted.

Previously, the Group had received the drug clinical trial approval notice for this product issued by the State Drug Administration of the People's Republic of China in July 2026, and commenced clinical trials of SYS 6090-007 after approval. The approved clinical trial is an open, multi-center phase Ib/II clinical trial aimed at evaluating the safety, tolerability, and efficacy of the combined treatment of this product in hepatocellular carcinoma participants.